See other companies on Welcome to the Jungle
Abtrace
Patient monitoring tool
- 21-100 employees
- Healthcare
- B2B
- Machine Learning
- SaaS
- Paddington, London, UK
Jump to section
Company mission
To transform healthcare by moving it from reactive to proactive through the safe and respectful application of technology and data.
Few candidates hear
back within 2 weeks
Our take
Abtrace is a health tech company specialising in AI-driven software that delivers individualised health interventions on a large scale. The product monitors patient health records to detect early signs of deterioration, new diseases, and opportunities for preventive care.
Abtrace is notable for its integration with primary care systems like EMIS and SystmOne, enabling proactive monitoring at over 250 practices. By automating monitoring, its tool aids healthcare workers to ensure timely and accurate interventions. This approach not only enhances patient care but also optimises efficiency by reducing the need for repeat appointments.
Having raised substantial funding, including a £2.1M seed round, Abtrace plans to expand its technological capabilities and workforce. Future goals include advancing the deployment of machine learning algorithms to detect early signs of serious conditions such as cancer, and further solidifying its role in transforming chronic disease management.
Freddie
Company Specialist at Welcome to the Jungle
Benefits
- Private Pension
- Generous maternity/paternity leave
- Flexi working & possibility for remote working
- Company's office in Paddington - easy commute and comfortable surroundings
- Motivated, highly functioning, multi-disciplinary team
- We'll equip you with laptop and any necessary gear
- As much freedom and independence as you earn, and a chance to grow rapidly as the company does
Funding (last 2 of 3 rounds)
Aug 2021
$2.7m
SEED
Nov 2020
$0.7m
GRANT
Total funding: $6.3m
This company has top investors
Leadership
Umar Naeem Ahmad
(CEO)Also a Fellow and Doctor for the NHS. Previously founded TIMED.
Helder Soares
(COO)Previously a Researcher for Luzitin. Also a PhD Student at the University of Coimbra.
Cristina Correia
(CCO)Prior work includes RDI Director/Senior Scientist for Stemmatters. Was also a PhD Researcher for both 3B´s Research Group and Columbia University.